Neuberger Berman Group’s TG Therapeutics TGTX Stock Holding History

Neuberger Berman Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$713K	Buy	12,984 +1,461	+13%	+$59.8K	﹤0.01%	1658
2026 Q1	$383K	Buy	11,523 +1,831	+19%	+$54.6K	﹤0.01%	1733
2025 Q4	$289K	Buy	9,692 +2,450	+34%	+$80K	﹤0.01%	1816
2025 Q3	$262K	Sell	7,242 -834	-10%	-$27.5K	﹤0.01%	1804
2025 Q2	$291K	Buy	8,076 +158	+2%	+$5.88K	﹤0.01%	1741
2025 Q1	$312K	Buy	+7,918	New	+$266K	﹤0.01%	1686
2013 Q4	–	Sell	-126,200	Closed	-$636K	–	1665
2013 Q3	$636K	Buy	+126,200	New	+$772K	﹤0.01%	1260

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Neuberger Berman Group's TGTX Position: Q2 2026 in Review

Neuberger Berman Group increased its TG Therapeutics (TGTX) stake by 13% in Q2 2026, buying an estimated $59.8K and bringing the position to 12,984 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #1658.

Neuberger Berman Group first reported a position in TGTX in Q3 2013 and has held it in 7 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Neuberger Berman Group held 12,984 shares of TG Therapeutics worth $713K as of Q2 2026.
Neuberger Berman Group bought 1,461 TG Therapeutics shares in Q2 2026, an estimated $59.8K.
TG Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1658 holding.
Neuberger Berman Group first reported a position in TG Therapeutics in Q3 2013 and has held it in 7 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.